Position in HLN
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$1,912
New position
Shares Held
205
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#574
of 639 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Oakmont Advisory Group, LLC holds $1,297,099 across 8 Drug Manufacturers - Specialty & Generic names. HLN ranks #7 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
2,639 | $444,777 | |
| 2 | ELAN |
Elanco Animal Health Inc
|
15,758 | $387,804 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
700 | $379,281 | |
| 4 | LNTH |
Lantheus Holdings, Inc.
|
376 | $41,713 | |
| 5 | HIMS |
Hims & Hers Health, Inc.
|
1,111 | $38,518 | |
| 6 | BHC |
Bausch Health Companies Inc.
|
527 | $2,598 | |
| 7 | HLN |
Haleon plc
This page
|
205 | $1,912 | |
| 8 | TAK |
Takeda Pharmaceutical Co Ltd
|
31 | $496 |
All Filings in HLN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,912 | 205 | Shares | Sole | 2026-08-03 | |
| No filing history on record for this holder in this stock. | ||||||